Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruben Bill

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
The Journal of Experimental Medicine|February 18, 2021
Tumor-infiltrating dendritic cell states are conserved across solid human cancersGenevieve M Gerhard, Ruben Bill, Marius Messemaker, et al.
Hepatology (Baltimore, Md.)|February 24, 2018
Favorable response to mammalian target of rapamycin inhibition in a young patient with unresectable fibrolamellar carcinoma of the liverRuben Bill, Matteo Montani, Benedikt Blum, et al.
Cell Reports|May 3, 2016
Targeting Metabolic Symbiosis to Overcome Resistance to Anti-angiogenic TherapyLaura Pisarsky, Ruben Bill, Ernesta Fagiani, et al.
Cancer Reports (Hoboken, N.J.)|July 7, 2021
Diagnostic challenges and successful organ-preserving therapy in a case of secretory carcinoma of minor salivary glandsRuben Bill, Daniel G Deschler, Mikael J Pittet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2015
Nintedanib Is a Highly Effective Therapeutic for Neuroendocrine Carcinoma of the Pancreas (PNET) in the Rip1Tag2 Transgenic Mouse ModelRuben Bill, Ernesta Fagiani, Adrian Zumsteg, et al.
Molecular Cancer Therapeutics|July 22, 2017
Autophagy Inhibition Improves Sunitinib Efficacy in Pancreatic Neuroendocrine Tumors via a Lysosome-dependent MechanismTabea Wiedmer, Annika Blank, Sophia Pantasis, et al.
Cell Reports. Medicine|May 1, 2025
Spatial analysis identifies DC niches as predictors of pembrolizumab therapy in head and neck squamous cell cancerJuhyun Oh, Jan Hoelzl, Jonathan C T Carlson, et al.
Oncotarget|April 2, 2016
A high-content EMT screen identifies multiple receptor tyrosine kinase inhibitors with activity on TGFβ receptorCarina Lotz-Jenne, Urs Lüthi, Sabine Ackerknecht, et al.
Developmental Cell|November 30, 2021
Distinct contributions of partial and full EMT to breast cancer malignancyFabiana Lüönd, Nami Sugiyama, Ruben Bill, et al.
Oncogenesis|September 22, 2018
The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancerStefanie Tiede, Nathalie Meyer-Schaller, Ravi Kiran Reddy Kalathur, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
The Journal of Experimental Medicine|February 18, 2021
Tumor-infiltrating dendritic cell states are conserved across solid human cancersGenevieve M Gerhard, Ruben Bill, Marius Messemaker, et al.
Hepatology (Baltimore, Md.)|February 24, 2018
Favorable response to mammalian target of rapamycin inhibition in a young patient with unresectable fibrolamellar carcinoma of the liverRuben Bill, Matteo Montani, Benedikt Blum, et al.
Cell Reports|May 3, 2016
Targeting Metabolic Symbiosis to Overcome Resistance to Anti-angiogenic TherapyLaura Pisarsky, Ruben Bill, Ernesta Fagiani, et al.
Cancer Reports (Hoboken, N.J.)|July 7, 2021
Diagnostic challenges and successful organ-preserving therapy in a case of secretory carcinoma of minor salivary glandsRuben Bill, Daniel G Deschler, Mikael J Pittet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2015
Nintedanib Is a Highly Effective Therapeutic for Neuroendocrine Carcinoma of the Pancreas (PNET) in the Rip1Tag2 Transgenic Mouse ModelRuben Bill, Ernesta Fagiani, Adrian Zumsteg, et al.
Molecular Cancer Therapeutics|July 22, 2017
Autophagy Inhibition Improves Sunitinib Efficacy in Pancreatic Neuroendocrine Tumors via a Lysosome-dependent MechanismTabea Wiedmer, Annika Blank, Sophia Pantasis, et al.
Cell Reports. Medicine|May 1, 2025
Spatial analysis identifies DC niches as predictors of pembrolizumab therapy in head and neck squamous cell cancerJuhyun Oh, Jan Hoelzl, Jonathan C T Carlson, et al.
Oncotarget|April 2, 2016
A high-content EMT screen identifies multiple receptor tyrosine kinase inhibitors with activity on TGFβ receptorCarina Lotz-Jenne, Urs Lüthi, Sabine Ackerknecht, et al.
Developmental Cell|November 30, 2021
Distinct contributions of partial and full EMT to breast cancer malignancyFabiana Lüönd, Nami Sugiyama, Ruben Bill, et al.
Oncogenesis|September 22, 2018
The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancerStefanie Tiede, Nathalie Meyer-Schaller, Ravi Kiran Reddy Kalathur, et al.
Pageof 3